Your browser doesn't support javascript.
loading
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial.
Ahn, Hee Kyung; Sim, Sung Hoon; Suh, Koung Jin; Kim, Min Hwan; Jeong, Jae Ho; Kim, Ji-Yeon; Lee, Dae-Won; Ahn, Jin-Hee; Chae, Heejung; Lee, Kyung-Hun; Kim, Jee Hyun; Lee, Keun Seok; Sohn, Joo Hyuk; Choi, Yoon-La; Im, Seock-Ah; Jung, Kyung Hae; Park, Yeon Hee.
Afiliación
  • Ahn HK; Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
  • Sim SH; Center for Breast Cancer, National Cancer Center, Goyang, Korea.
  • Suh KJ; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  • Kim MH; Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • Jeong JH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Kim JY; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Lee DW; Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
  • Ahn JH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Chae H; Center for Breast Cancer, National Cancer Center, Goyang, Korea.
  • Lee KH; Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
  • Kim JH; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  • Lee KS; Center for Breast Cancer, National Cancer Center, Goyang, Korea.
  • Sohn JH; Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • Choi YL; Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Im SA; Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
  • Jung KH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Park YH; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
JAMA Oncol ; 8(9): 1271-1277, 2022 09 01.
Article en En | MEDLINE | ID: mdl-35797012
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Terapia Neoadyuvante Tipo de estudio: Clinical_trials Límite: Female / Humans / Middle aged Idioma: En Revista: JAMA Oncol Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Terapia Neoadyuvante Tipo de estudio: Clinical_trials Límite: Female / Humans / Middle aged Idioma: En Revista: JAMA Oncol Año: 2022 Tipo del documento: Article